Evidence map›Paper›PMID 38497714›Full record

ArticleMicrobiology spectrum2024

How much should we sequence? An analysis of the Swiss SARS-CoV-2 surveillance effort.

Fanny Wegner, Blanca Cabrera-Gil, Araud Tanguy, Christiane Beckmann, Niko Beerenwinkel, Claire Bertelli, Matteo Carrara, Lorenzo Cerutti, Chaoran Chen, Samuel Cordey and 39 more

Abstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Improving public health laboratory preparedness at European Union level: learning points from experiences during the COVID-19 pandemic.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

49 authors.

Fanny Wegner *Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-4348-5872
Blanca Cabrera-Gil *Clinical Bioinformatics, SIB Swiss Institute of Bioinformatics, Geneva, Switzerland.
Araud TanguyGenesupport, Geneva, Switzerland.
Christiane BeckmannViollier AG, Allschwil, Switzerland.
Niko BeerenwinkelDepartment of Biosystems Science and Engineering, ETH Zurich, Switzerland & SIB Swiss Institute of Bioinformatics, Basel, Switzerland.
Claire BertelliClinical Microbiology, University Hospital, Lausanne, Switzerland.ORCID 0000-0003-0550-8981
Matteo CarraraNEXUS Personalized Health Technologies, ETH Zurich, Switzerland & SIB Swiss Institute of Bioinformatics, Basel, Switzerland.
Lorenzo CeruttiHealth2030 Genome Center, Geneva, Switzerland.
Chaoran ChenDepartment of Biosystems Science and Engineering, ETH Zurich, Switzerland & SIB Swiss Institute of Bioinformatics, Basel, Switzerland.
Samuel CordeyLaboratory of Virology, Geneva University Hospitals, Geneva, Switzerland.
Alexis DumoulinValais Hospital, Central Institute, Sion, Switzerland.
Louis du PlessisDepartment of Biosystems Science and Engineering, ETH Zurich, Switzerland & SIB Swiss Institute of Bioinformatics, Basel, Switzerland.
Marc FriedliHealth2030 Genome Center, Geneva, Switzerland.
Yannick GerthHumanmedizinische Mikrobiologie, Zentrum für Labormedizin, St. Gallen, Switzerland.
Gilbert GreubClinical Microbiology, University Hospital, Lausanne, Switzerland.ORCID 0000-0001-9529-3317
Adrian HärriBiolytix, Witterswil, Switzerland.
Hans HirschClinical Virology, University Hospital, Basel, Switzerland.ORCID 0000-0003-0883-0423
Cedric HowaldHealth2030 Genome Center, Geneva, Switzerland.
Michael HuberInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
Alexander ImhofSpitalregion Oberaargau, Langenthal, Switzerland.
Laurent KaiserLaboratory of Virology, Geneva University Hospitals, Geneva, Switzerland.
Verena KufnerInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
Stephen L LeibInstitute for Infectious Diseases (IFIK), University of Bern, Bern, Switzerland.ORCID 0000-0002-1106-6123
Karoline LeuzingerClinical Virology, University Hospital, Basel, Switzerland.ORCID 0000-0002-5654-9356
Etleva LleshiMicrobiology Department, Synlab, Bioggio, Switzerland.
Gladys MartinettiDepartment of Laboratory Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Mirjam MäusezahlFederal Office of Public Health, Bern, Switzerland.
Milo MorazValais Hospital, Central Institute, Sion, Switzerland.
Richard NeherBiozentrum, University of Basel, Switzerland & SIB Swiss Institute of Bioinformatics, Basel, Switzerland.ORCID 0000-0003-2525-1407
Oliver NolteHumanmedizinische Mikrobiologie, Zentrum für Labormedizin, St. Gallen, Switzerland.
Alban RametteInstitute for Infectious Diseases (IFIK), University of Bern, Bern, Switzerland.ORCID 0000-0002-3437-4639
Maurice RedondoViollier AG, Allschwil, Switzerland.
Lorenz RischLabor Dr. Risch, Buchs, Switzerland.
Lionel RohnerFederal Office of Public Health, Bern, Switzerland.
Tim RoloffInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
Pascal SchläepferClinical Microbiology, University Hospital, Basel, Switzerland.
Katrin SchneiderFederal Office of Public Health, Bern, Switzerland.
Franziska SingerNEXUS Personalized Health Technologies, ETH Zurich, Switzerland & SIB Swiss Institute of Bioinformatics, Basel, Switzerland.
Valeria SpinaDepartment of Laboratory Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Tanja StadlerDepartment of Biosystems Science and Engineering, ETH Zurich, Switzerland & SIB Swiss Institute of Bioinformatics, Basel, Switzerland.
Erik StuderFederal Office of Public Health, Bern, Switzerland.
Ivan TopolskyDepartment of Biosystems Science and Engineering, ETH Zurich, Switzerland & SIB Swiss Institute of Bioinformatics, Basel, Switzerland.
Alexandra TrkolaInstitute of Medical Virology, University of Zurich, Zurich, Switzerland.
Daniel WaltherClinical Bioinformatics, SIB Swiss Institute of Bioinformatics, Geneva, Switzerland.
Nadia WohlwendLabor Dr. Risch, Buchs, Switzerland.
Cinzia ZehnderMicrobiology Department, Synlab, Bioggio, Switzerland.
Aitana Neves *Clinical Bioinformatics, SIB Swiss Institute of Bioinformatics, Geneva, Switzerland.
Adrian Egli *Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-3564-8603
SPSP consortium

Funding

Federal Office of Public HealthGottfried und Julia Bangerter-Rhyner-Stiftung (Bangerter-Stiftung)Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) 310030_192515SERISwiss National Science Foundation, National Research Program 72 407240_177504swissuniversities openscience
6 · The paper itself

Abstract

During the SARS-CoV-2 pandemic, many countries directed substantial resources toward genomic surveillance to detect and track viral variants. There is a debate over how much sequencing effort is necessary in national surveillance programs for SARS-CoV-2 and future pandemic threats. We aimed to investigate the effect of reduced sequencing on surveillance outcomes in a large genomic data set from Switzerland, comprising more than 143k sequences. We employed a uniform downsampling strategy using 100 iterations each to investigate the effects of fewer available sequences on the surveillance outcomes: (i) first detection of variants of concern (VOCs), (ii) speed of introduction of VOCs, (iii) diversity of lineages, (iv) first cluster detection of VOCs, (v) density of active clusters, and (vi) geographic spread of clusters. The impact of downsampling on VOC detection is disparate for the three VOC lineages, but many outcomes including introduction and cluster detection could be recapitulated even with only 35% of the original sequencing effort. The effect on the observed speed of introduction and first detection of clusters was more sensitive to reduced sequencing effort for some VOCs, in particular Omicron and Delta, respectively. A genomic surveillance program needs a balance between societal benefits and costs. While the overall national dynamics of the pandemic could be recapitulated by a reduced sequencing effort, the effect is strongly lineage-dependent-something that is unknown at the time of sequencing-and comes at the cost of accuracy, in particular for tracking the emergence of potential VOCs.IMPORTANCESwitzerland had one of the most comprehensive genomic surveillance systems during the COVID-19 pandemic. Such programs need to strike a balance between societal benefits and program costs. Our study aims to answer the question: How would surveillance outcomes have changed had we sequenced less? We find that some outcomes but also certain viral lineages are more affected than others by sequencing less. However, sequencing to around a third of the original effort still captured many important outcomes for the variants of concern such as their first detection but affected more strongly other measures like the detection of first transmission clusters for some lineages. Our work highlights the importance of setting predefined targets for a national genomic surveillance program based on which sequencing effort should be determined. Additionally, the use of a centralized surveillance platform facilitates aggregating data on a national level for rapid public health responses as well as post-analyses.

Indexed as

COVID-19Genome, ViralSARS-CoV-2Epidemiological MonitoringHumansPandemicsPhylogenySwitzerlandgenomic surveillancemodelingmolecular epidemiologyplatformpublic healthSARS-CoV-2surveillance studieswhole genome sequencing

Identifiers

PMID38497714
PMCPMC11064629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.